Plant Name: Papaver sommiferum
Taxonomic Information:
Plant ID: NPO31048
Plant Latin Name: Papaver sommiferum
Taxonomy Genus: Papaver
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Italy; JordanTraditional Medicine System:
Geographical Distribution:
Jordan; Italy
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD3; DRD1; DRD2; | |
| PDE10A; | |
| PDE3A; | |
| GFER; SENP6; | |
| LMNA; SIGMAR1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | SENP6 | Sentrin-specific protease 6 | Q9GZR1 | CHEMBL1741215 |
| Phosphodiesterase 10 | PDE10A | Phosphodiesterase 10A | Q9Y233 | CHEMBL4409 |
| Phosphodiesterase 3 | PDE3A | Phosphodiesterase 3A | Q14432 | CHEMBL241 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 7.682E-09 | 8.364E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 3.917E-08 | 1.706E-04 | DRD1, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.917E-08 | 1.706E-04 | DRD1, DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.558E-07 | 3.084E-04 | DRD1, DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 3.547E-07 | 5.941E-04 | DRD1, DRD2, DRD3 |
| BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 4.466E-07 | 6.946E-04 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 8.842E-07 | 1.284E-03 | DRD2, DRD3 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 2.343E-06 | 2.430E-03 | DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 2.946E-06 | 2.673E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 2.946E-06 | 2.673E-03 | DRD2, DRD3 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.417E-06 | 3.317E-03 | CYP2C19, CYP2D6 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 8.240E-06 | 5.202E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 1.323E-05 | 6.862E-03 | DRD1, DRD3 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 1.323E-05 | 6.862E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 1.323E-05 | 6.862E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 1.617E-05 | 7.336E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 1.617E-05 | 7.336E-03 | DRD2, DRD3 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 1.617E-05 | 7.336E-03 | DRD1, DRD2 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 1.940E-05 | 8.621E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0030817; regulation of cAMP biosynthetic process | 2.029E-05 | 8.835E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 2.292E-05 | 9.597E-03 | DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 2.292E-05 | 9.597E-03 | DRD2, DRD3 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09164 Substance dependence | hsa05032 | Morphine addiction | 1.464E-05 | 3.661E-04 | PDE10A, PDE3A, DRD1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 4.165E-05 | 5.206E-04 | DRD1, DRD2, DRD3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.510E-04 | 1.258E-03 | PDE3A, DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 3.189E-04 | 1.993E-03 | DRD1, DRD2 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.994E-04 | 1.997E-03 | DRD1, DRD2, DRD3 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.323E-04 | 2.635E-03 | CYP2D6, CYP2C19 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.026E-03 | 3.664E-03 | DRD1, DRD2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.654E-03 | 5.169E-03 | CYP2D6, CYP2C19 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 2.640E-03 | 7.333E-03 | DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 4.155E-03 | 9.442E-03 | DRD1, DRD2 |
| 09100 Metabolism | 09104 Nucleotide metabolism | hsa00230 | Purine metabolism | 4.020E-03 | 9.442E-03 | PDE10A, PDE3A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; DRD3; PDE10A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; DRD2; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| NA: NA | Schizoaffective disorder | NA | PDE10A; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; DRD3; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| NA: NA | Vomiting | NA | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; PDE10A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| NA: NA | Itching | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; DRD3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
